technology

Enveda Raises $311 Million to Advance Nature-Derived AI Drug Trials

23 Eylül 2026TechCrunch

Enveda has secured $311 million in funding, valuing the company at $2 billion, to advance clinical trials for AI-driven drugs.
Enveda has successfully raised $311 million in funding, bringing its valuation to $2 billion. The biotech company focuses on developing AI-driven drugs derived from natural sources, currently testing treatments for skin conditions and methods to maintain weight loss after discontinuing GLP-1 medications.
This significant investment highlights the growing interest in combining artificial intelligence with biotechnology.
Enveda's focus on nature-derived AI drugs aligns with a broader movement in healthcare towards personalized medicine and sustainable drug development. The company's work on GLP-1 alternatives is particularly relevant given the rising popularity of these medications for weight loss, making their ongoing research crit…
The substantial funding round for Enveda underscores a promising trend in the biotech industry, where AI is increasingly leveraged to discover and develop novel therapeutics. As the company explores nature-derived drugs, it could potentially disrupt traditional pharmaceutical approaches, particularly in the realm of…

NewsAI özeti

This summary is based on information available as of October 2023 and may not reflect the latest developments.

Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.

Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.